Aequim Alternative Investments’s Supernus Pharmaceuticals SUPN Stock Holding History

Aequim Alternative Investments’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-46,400	Closed	-$1.17M	–	99
2020 Q4	$1.17M	Hold	46,400	–	–	0.09%	69
2020 Q3	$967K	Hold	46,400	–	–	0.13%	60
2020 Q2	$1.1M	Hold	46,400	–	–	0.17%	54
2020 Q1	$835K	Sell	46,400 -69,800	-60%	-$1.47M	0.14%	52
2019 Q4	$2.76M	Hold	116,200	–	–	0.51%	40
2019 Q3	$3.19M	Hold	116,200	–	–	0.64%	32
2019 Q2	$3.85M	Buy	116,200 +23,200	+25%	+$795K	1.09%	21
2019 Q1	$3.26M	Buy	93,000 +34,800	+60%	+$1.29M	1.16%	22
2018 Q4	$1.93M	Buy	+58,200	New	+$2.5M	0.98%	20

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

ACM

Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Aequim Alternative Investments's SUPN Position: Q1 2021 in Review

Aequim Alternative Investments sold out of Supernus Pharmaceuticals (SUPN) in Q1 2021, closing a stake of 46,400 shares — an estimated $1.17M sold.

Aequim Alternative Investments first reported a position in SUPN in Q4 2018 and held it in 9 quarters. The position peaked at $3.85M in Q2 2019. 224 funds tracked by Wall St. Rank hold SUPN as of Q1 2021.

Aequim Alternative Investments reported no remaining Supernus Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Aequim Alternative Investments sold 46,400 Supernus Pharmaceuticals shares in Q1 2021, an estimated $1.17M.
Aequim Alternative Investments first reported a position in Supernus Pharmaceuticals in Q4 2018 and held it in 9 quarters.
Aequim Alternative Investments's Supernus Pharmaceuticals position peaked at $3.85M in Q2 2019.
224 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2021.

Based on Aequim Alternative Investments's 13F filing for Q1 2021, filed 12 May 2021.